bluebird bio Receives Positive Opinion from CHMP for ZYNTEGLO (autologous CD34+ cells encoding A-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 29, 2019--bluebird bio, Inc. (Nasdaq:BLUE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Med…
